another flop

A board to discuss future MS therapies in early stage (Phase I or II) trials.

another flop

Postby scorpion » Mon Sep 28, 2009 7:50 am

ZymoGenetics Partner Halts Multiple Sclerosis Trials After Drug Fails
Luke Timmerman 9/28/09

More bad news out of ZymoGenetics (NASDAQ: ZGEN) this morning. The Seattle-based biotech company disclosed in a regulatory filing today that its partner, Germany-based pharmaceutical giant Merck KGaA, has halted studies of their atacicept drug candidate for multiple sclerosis after concluding the drug’s benefit wasn’t worth the risk.

One trial showed that multiple sclerosis patients actually had more flare-ups and brain lesions when they were given atacicept, compared with a placebo. Two studies are still ongoing of atacicept, one for rheumatoid arthritis and one for lupus, and no com
User avatar
Family Elder
Posts: 1323
Joined: Wed Nov 05, 2008 4:00 pm


Postby dignan » Mon Sep 28, 2009 8:53 am

Thanks for the update scorpion...damn.
User avatar
Family Elder
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service